Harvoni

How AbbVie Could Hammer Gilead's Hepatitis C Franchise
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
Flag link:
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
Forbes
drug pricing
hepatitis C
Martin Shkreli
Gilead Sciences
Harvoni
Sovaldi
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
Gilead works on lifecycle management for Sovaldi as Hep C franchise wanes
Gilead works on lifecycle management for Sovaldi as Hep C franchise wanes
BioPharma Dive
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:
Gilead Hep C Drugs Get Supplemental FDA Nod
Gilead Hep C Drugs Get Supplemental FDA Nod
Investopedia
Gilead Sciences
hepatitis C
FDA
Harvoni
Sovaldi
Flag link:
Gilead's Harvoni ads go from before to after with new creative focused on hep C cure
Gilead's Harvoni ads go from before to after with new creative focused on hep C cure
Fierce Pharma
Gilead Sciences
Harvoni
drug ads
DTC ads
hepatitis C
Flag link:
Gilead pushes hep C testing in baby boomers as its blockbusters plummet
Gilead pushes hep C testing in baby boomers as its blockbusters plummet
Fierce Pharma
Gilead Sciences
hepatitis C
baby boomers
DTC advertising
Harvoni
Sovaldi
Flag link:
Gilead cured hepatitis C. That’s become its biggest problem
Gilead cured hepatitis C. That’s become its biggest problem
Marketwatch
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:
Gilead’s Biggest Blockbusters Are Fading Fast, Biotech Warns
Gilead’s Biggest Blockbusters Are Fading Fast, Biotech Warns
Bloomberg
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:
Has Gilead Sciences' Cash Cow Finally Hit Bottom?
Has Gilead Sciences' Cash Cow Finally Hit Bottom?
Motley Fool
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:
The Most Expensive Drugs of 2016
The Most Expensive Drugs of 2016
Motley Fool
drug pricing
Gilead Sciences
Harvoni
Sovaldi
H.P. Acthar
Mallinckrodt
Shire
Cinryze
Daklinza
Bristol-Myers Squibb
Flag link:
Gilead’s Patent Loss to Merck Started With a Broken Friendship
Gilead’s Patent Loss to Merck Started With a Broken Friendship
Bloomberg
Gilead Sciences
Merck
patents
hepatitis C
Sovaldi
Harvoni
Flag link:
Merck Wins Record $2.5 Billion Patent Verdict Against Gilead
Merck Wins Record $2.5 Billion Patent Verdict Against Gilead
Bloomberg
Merck
patents
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
5 Most Expensive Medicare Drugs -- and Which Companies Are Getting Rich From Them
5 Most Expensive Medicare Drugs -- and Which Companies Are Getting Rich From Them
Motley Fool
Medicare
H.P. Acthar Gel
Mallinckrodt
Remodulin
United Therapeutics
Tyvaso
Provenge
Valeant Pharmaceuticals
Gilead Sciences
Harvoni
Flag link:
Gilead hepatitis C pill was biggest 2015 drug cost for Medicare, Medicaid
Gilead hepatitis C pill was biggest 2015 drug cost for Medicare, Medicaid
Stat/Pharmalot
Gilead Sciences
hepatitis C
Medicare
Medicaid
Harvoni
Flag link:
Unfazed by FDA Warning, Gilead Sciences' Stock Could Be Turning a Corner
Unfazed by FDA Warning, Gilead Sciences' Stock Could Be Turning a Corner
Motley Fool
FDA
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
How Gilead Dominates the HCV Space
How Gilead Dominates the HCV Space
Market Realist
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:
Gilead Sciences: Are Hepatitis C Sales Getting Better?
Gilead Sciences: Are Hepatitis C Sales Getting Better?
Barron's
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
Gilead to get attorney fees in hepatitis C patent fight with Merck
Gilead to get attorney fees in hepatitis C patent fight with Merck
Yahoo/Reuters
Gilead Sciences
Merck
hepatitis C
Sovaldi
Harvoni
Flag link:
As hep C sales decline, Wall Street wonders what Gilead does for its next act
As hep C sales decline, Wall Street wonders what Gilead does for its next act
Stat
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link: